Most antibiotics are made by growing microorganisms in large industrial tanks, then extracting and purifying the compounds those organisms naturally produce. Some are further modified through chemical reactions to make them more effective, and a small number are built entirely from scratch in a chemistry lab. The process from raw fermentation to a finished pill or injectable involves biology, chemistry, and rigorous quality testing at every stage.
Fermentation: Where Most Antibiotics Begin
The majority of antibiotics originate from living organisms, usually bacteria or fungi that evolved to produce these compounds as chemical weapons against competing microbes. Penicillin, for example, comes from a mold. Streptomycin comes from soil bacteria. To make antibiotics at scale, manufacturers essentially farm these organisms under tightly controlled conditions.
The process starts with a carefully maintained “seed culture,” a small sample of the antibiotic-producing organism grown in a flask. That culture gets transferred into progressively larger vessels until it reaches an industrial bioreactor, a stainless steel tank fitted with sensors, gas exchange ports, pressure valves, and filters. These bioreactors typically range from 50 to 2,000 liters in pharmaceutical production, though some facilities use even larger vessels. Inside the tank, the organism is fed a nutrient broth (carbon sources like sugar, nitrogen sources, and trace minerals) while temperature, pH, and oxygen levels are monitored constantly. Oxygen transport is especially critical because many antibiotic-producing organisms are aerobic, meaning they need a steady supply of dissolved oxygen to grow and synthesize their products.
A single fermentation batch can run for days or weeks depending on the antibiotic. Some cycles last around a week, while extended fed-batch processes, where nutrients are added gradually over time, can run for 25 days or longer. These longer cycles can yield significantly more product, with one study finding a 2.5-fold increase in productivity compared to standard batch fermentation. Throughout the process, small samples are pulled to check whether the organism is healthy and producing the target compound at expected levels.
Extracting the Active Compound
When fermentation finishes, the broth is a messy mixture of living and dead cells, leftover nutrients, waste products, and the antibiotic itself dissolved or suspended in the liquid. The next job is to isolate just the antibiotic from everything else.
The first step is usually separating the cells from the liquid, typically through filtration or centrifugation. Whether the antibiotic ends up in the liquid portion or stays bound to the cells depends on the specific compound. For antibiotics secreted into the broth, the liquid (called the supernatant) moves on to extraction. For those trapped inside cells, the cells need to be broken open first.
From there, manufacturers use a combination of techniques to pull the antibiotic out of solution. Solvent extraction is common: the broth is mixed with an organic solvent like chloroform or butyl acetate that the antibiotic dissolves into more readily than water. The two liquids naturally separate into layers, and the antibiotic-rich solvent layer is collected. Another approach is precipitation, where adding a salt like ammonium sulfate at high concentrations forces the antibiotic (or antibiotic-like proteins, in the case of peptide antibiotics) out of solution so it can be collected as a solid. Ion exchange resins, which attract molecules based on their electrical charge, are also widely used to grab the target compound while letting impurities pass through.
These steps are repeated and refined to increase purity. High-performance liquid chromatography (HPLC) is a workhorse technique in the later stages. The partially purified antibiotic is pushed through a column packed with specialized material, and different compounds emerge at different times based on their chemical properties. By collecting only the fraction that comes out at the right time, manufacturers can achieve very high purity. The final product is often crystallized to produce a stable, uniform powder ready for formulation into tablets, capsules, or injectable solutions.
Semi-Synthetic Antibiotics: Modifying Nature’s Blueprint
Many of the most widely prescribed antibiotics aren’t used exactly as nature makes them. Instead, chemists take a naturally produced compound and tweak its structure to improve it. This approach, called semi-synthesis, has produced more than fifty commercial antibiotics from just two key starting molecules in the penicillin and cephalosporin families alone.
The strategy works by first producing a core molecule through fermentation, then chemically attaching or removing specific groups of atoms. For penicillin-type drugs, the core molecule is called 6-APA. For cephalosporins, it’s 7-ACA. Chemists modify these cores by attaching different side chains at specific positions on the molecule, which changes how the drug behaves in the body: how well it penetrates bacterial cell walls, how resistant it is to the enzymes bacteria use to break down antibiotics, and which species of bacteria it can kill. This is how a single mold-derived compound led to an entire family of drugs including amoxicillin, ampicillin, and dozens of others.
The same principle applies across other antibiotic families. The first semi-synthetic tetracycline was created at Pfizer in the 1950s by breaking a single carbon-chlorine bond in a naturally occurring compound. Later modifications involved removing a specific chemical group from the molecule’s backbone, which opened the door to drugs like minocycline. For macrolide antibiotics (the family that includes erythromycin), Japanese researchers developed a six-step chemical process to add a single methyl group to erythromycin at just the right position, creating clarithromycin, a version that’s more stable in stomach acid and causes fewer side effects.
These chemical modifications sound small, but they can dramatically change a drug’s effectiveness. When bacteria evolved enzymes that could destroy third-generation cephalosporins, chemists responded by redesigning the side chains to create fourth-generation versions that those enzymes couldn’t break down.
Fully Synthetic Antibiotics
A smaller number of antibiotics are built entirely through chemical synthesis, with no biological starting material. Sulfonamides, the first class of antibiotics ever used clinically, are synthetic. So are fluoroquinolones like ciprofloxacin and the oxazolidinone linezolid. These drugs are assembled step by step from simple chemical building blocks in reactor vessels, using carefully sequenced reactions to construct the final molecule.
Fully synthetic production gives chemists complete freedom to design molecules that don’t exist in nature, but it’s also more technically demanding. Complex antibiotics can require dozens of sequential chemical reactions, each of which needs to proceed efficiently and produce the right three-dimensional arrangement of atoms. For many antibiotics, fermentation followed by semi-synthesis remains cheaper and more practical than total synthesis.
Quality Testing Before Release
Before any antibiotic reaches a pharmacy, it goes through a battery of tests mandated by regulatory agencies. For injectable antibiotics, FDA current good manufacturing practices require testing for sterility (confirming no contaminating organisms are present), endotoxin levels (bacterial toxins that can cause dangerous immune reactions), identity (confirming the drug is what it’s supposed to be), potency (verifying the correct strength), and purity (ensuring contaminants fall below acceptable thresholds).
Sterility testing follows standardized protocols. If manufacturers use alternative testing methods instead of the standard ones, those methods must be fully validated to prove they’re equally reliable. Potency testing confirms that each batch delivers the labeled dose of active ingredient. These aren’t optional checks: failing any of them means the batch doesn’t ship.
Oral antibiotics face their own set of requirements, including dissolution testing (how quickly the tablet breaks down) and stability testing (how long the drug maintains its potency under various storage conditions). The entire manufacturing process, from the seed culture through final packaging, is documented in detail so regulators can trace any problem back to its source.
How AI Is Changing the Process
The traditional path from discovering an antibiotic to manufacturing it at scale takes years. New technology is compressing that timeline, particularly in the discovery phase. Researchers have recently combined artificial intelligence with robotic synthesis platforms to screen enormous numbers of candidate compounds in days rather than months.
In one recent project, scientists used machine learning to evaluate 13,728 possible antimicrobial polymer combinations and identified 7 leading candidates in just 12 days. The system used a robotic liquid-handling platform connected to automated testing equipment, completing work in about 10 hours that would have taken 120 hours by hand, a 12-fold improvement in speed. The AI component used a technique called multi-objective Bayesian optimization to predict which combinations were most likely to kill bacteria while remaining safe for human cells, dramatically narrowing the search space before any physical synthesis began.
These platforms don’t replace fermentation or chemical synthesis for actual manufacturing, but they accelerate the bottleneck of figuring out which molecules are worth manufacturing in the first place. Given that antibiotic resistance is outpacing the development of new drugs, that speed matters.